Glendon French III Sells 8,805 Shares of Pulmonx (NASDAQ:LUNG) Stock

Pulmonx Corporation (NASDAQ:LUNG) CEO Glendon French III sold 8,805 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $1.57, for a total value of $13,823.85. Following the completion of the sale, the chief executive officer owned 277,324 shares in the company, valued at approximately $435,398.68. This trade represents a 3.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Pulmonx Trading Up 13.2%

Shares of Pulmonx stock opened at $2.14 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.86 and a quick ratio of 4.15. The business has a fifty day simple moving average of $1.69 and a two-hundred day simple moving average of $2.16. Pulmonx Corporation has a 1 year low of $1.31 and a 1 year high of $9.37. The company has a market capitalization of $88.28 million, a price-to-earnings ratio of -1.52 and a beta of 0.22.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.06. The company had revenue of $21.50 million for the quarter, compared to analyst estimates of $20.78 million. Pulmonx had a negative net margin of 61.91% and a negative return on equity of 77.58%. Research analysts forecast that Pulmonx Corporation will post -1.55 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Lake Street Capital dropped their price target on Pulmonx from $8.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, October 28th. D. Boral Capital restated a “buy” rating and issued a $14.00 price target on shares of Pulmonx in a research note on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $6.81.

Institutional Investors Weigh In On Pulmonx

Hedge funds and other institutional investors have recently made changes to their positions in the business. Deutsche Bank AG grew its position in Pulmonx by 4.2% during the first quarter. Deutsche Bank AG now owns 1,147,105 shares of the company’s stock worth $7,720,000 after buying an additional 46,116 shares in the last quarter. Vestal Point Capital LP acquired a new position in Pulmonx in the 3rd quarter valued at $1,345,000. GSA Capital Partners LLP lifted its position in shares of Pulmonx by 78.3% during the 3rd quarter. GSA Capital Partners LLP now owns 755,467 shares of the company’s stock valued at $1,224,000 after acquiring an additional 331,742 shares during the period. Parkman Healthcare Partners LLC grew its holdings in shares of Pulmonx by 194.4% during the 1st quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company’s stock worth $4,118,000 after purchasing an additional 404,022 shares in the last quarter. Finally, Bank of America Corp DE increased its position in shares of Pulmonx by 556.6% in the second quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock worth $1,246,000 after purchasing an additional 407,971 shares during the period. 91.04% of the stock is currently owned by institutional investors and hedge funds.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.